The adalimumab market is expected to show negative growth during the forecast period 2020-2026. Adalimumab is sold by AbbVie Inc., under the brand name of Humira. It was the first approved treatment of rheumatoid arthritis in the US in 2002 and in the EU in 2003. Humira is a biological therapy administered as a subcutaneous injection. In 2019, Humira accounted for around 58% of the total net revenue of AbbVie Inc., with revenue of $19.1 billion as compared to $19.9 billion in 2018. The high cost of the Humira is able to provide a significant market to the adalimumab market. It is due to the high annual costs of the drug. For instance, in the US, the annual cost of using Humira was around $19,000 in 2012 which has risen to around $38,000 with rebates in 2018 and about $50,000 without rebates.
Get Free Sample Copy @ https://www.omrglobal.com/request-sample/adalimumab-market
Increasing prevalence of arthritis, Crohn’s diseases, and increasing per capita healthcare expenditure in the emerging economies, are some of the factors contributing to the growth of the adalimumab market, however; loss of branded drug patent and approval to biosimilars are among the key factors for the downfall in revenue of the drug. AbbVie Inc. has lost its EU patent in 2017 however the company obtained Supplementary Protection Certificates (SPCs) which offered patent protection until 16th October 2018 to the company. Moreover, the initial US composition patent of the drug expired in December 2016.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/adalimumab-market
It was expected that after the expiration of the patent, multiple global companies will start manufacturing biosimilar of Humira; however, AbbVie Inc. is still continuing its monopoly in the market. It is due to the fact, that AbbVie Inc. has made an agreement with other biosimilar manufacturing companies for not to manufacture biosimilar (such as Boehringer Ingelheim International GmbH, Novartis AG, Amgen Inc.) till 2023 due to which the company is expected to maintain its monopoly for next three to four years in the US market, which is the largest market for adalimumab globally. However, after 2023, a significant drop in the Humira revenue is expected, which will provide a negative CAGR to the market during the forecast period. Moreover, the availability of an alternative of adalimumab is also expected to restrain market growth in the near future. Drugs such as Cimzia, Enbrel, Remicade, and Simponi are available in the market to treat rheumatoid arthritis and Crohn's disease.
Market Segmentation
Global Adalimumab Market by Disease
• Rheumatoid arthritis
• Psoriatic arthritis
• Crohn's disease
• Ulcerative colitis
• Others
Global Adalimumab Market by Type
• Branded
• Generic
Regional Analysis
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• Rest of Asia-Pacific
Rest of the World
Company Profiles
• AbbVie Inc.
• Alvotech hf
• Amgen Inc.
• Bio-Thera Solutions Ltd.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• Cadila Healthcare Ltd.
• Emcure Pharmaceuticals Ltd.
• Fujifilm Kyowa Kirin Biologics Co. Ltd.
• Hetero Healthcare Ltd.
• Innovent Biologics, Inc.
• Merchant Logo
• Novartis International AG (Sandoz)
• Pfizer Inc.
• Reliance Life Sciences Pvt. Ltd.
• Samsung Bioepis Co. Ltd
• Terumo Corp.
• Torrent Pharmaceuticals Ltd.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/adalimumab-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404